For help on how to get the results you want, see our search tips.
45 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Summaries of opinion Remove Summaries of opinion filter
Categories
Human Remove Human filter
Medicine type
Conditional approval Remove Conditional approval filter
-
List item
Human medicine European public assessment report (EPAR): Caprelsa
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,
, 
, Revision: 18, Authorised, Last updated: 07/12/2020
-
List item
Human medicine European public assessment report (EPAR): Rozlytrek
Entrectinib, Cancer, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 31/07/2020,, , Authorised, Last updated: 27/10/2020
-
List item
Human medicine European public assessment report (EPAR): Hepcludex
Bulevirtide acetate, Hepatitis D, Chronic
Date of authorisation: 31/07/2020,, 
, , Revision: 1, Authorised, Last updated: 07/10/2020
-
List item
Human medicine European public assessment report (EPAR): Vitrakvi
larotrectinib sulfate, Abdominal Neoplasms
Date of authorisation: 19/09/2019,, , Revision: 2, Authorised, Last updated: 29/09/2020
-
List item
Human medicine European public assessment report (EPAR): Waylivra
Volanesorsen sodium, Hyperlipoproteinemia Type I
Date of authorisation: 03/05/2019,, , , Revision: 2, Authorised, Last updated: 19/05/2020
-
List item
Human medicine European public assessment report (EPAR): Sirturo
bedaquiline fumarate, Tuberculosis, Multidrug-Resistant
Date of authorisation: 05/03/2014,, , , Revision: 17, Authorised, Last updated: 06/03/2020
-
List item
Human medicine European public assessment report (EPAR): Zalmoxis
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
Date of authorisation: 18/08/2016,, Revision: 1, Withdrawn, Last updated: 14/02/2020
-
List item
Human medicine European public assessment report (EPAR): Lartruvo
Olaratumab, Sarcoma
Date of authorisation: 09/11/2016,, 
, , Revision: 3, Withdrawn, Last updated: 02/09/2019
-
List item
Human medicine European public assessment report (EPAR): Arepanrix
split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 23/03/2010,, Revision: 1, Withdrawn, Last updated: 25/10/2011
-
List item
Human medicine European public assessment report (EPAR): Humenza
split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs., Influenza, Human, Immunization, Disease Outbreaks
Date of authorisation: 08/06/2010,, Withdrawn, Last updated: 30/06/2011
-
List item
Human medicine European public assessment report (EPAR): Idefirix
Imlifidase, Desensitization, Immunologic, Kidney Transplantation
Date of authorisation: 25/08/2020,, , , Authorised, Last updated: 28/08/2020
-
List item
Human medicine European public assessment report (EPAR): Adakveo
Crizanlizumab, Anemia, Sickle Cell
Date of authorisation: 28/10/2020,, , , Authorised, Last updated: 24/11/2020
-
List item
Human medicine European public assessment report (EPAR): Tecartus
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured, Lymphoma, Mantle-Cell
Date of authorisation: 14/12/2020,, , , Authorised, Last updated: 25/01/2021
-
List item
Human medicine European public assessment report (EPAR): Enhertu
trastuzumab deruxtecan, Breast Neoplasms
Date of authorisation: 18/01/2021,, , Authorised, Last updated: 08/02/2021
-
List item
Human medicine European public assessment report (EPAR): Retsevmo (new)
Selpercatinib, Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Date of authorisation: 11/02/2021,, , Authorised, Last updated: 23/04/2021
-
List item
Human medicine European public assessment report (EPAR): Jemperli (new)
dostarlimab, Endometrial Neoplasms
Date of authorisation: 21/04/2021,, , Authorised, Last updated: 03/05/2021
-
List item
Human medicine European public assessment report (EPAR): Pemazyre (new)
pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021,, , , Authorised, Last updated: 04/05/2021
-
List item
Summary of opinion: Sirturo
bedaquiline, opinion date: 28/01/2021, Positive, Last updated: 01/02/2021 -
List item
Summary of opinion: Nexpovio
selinexor, opinion date: 28/01/2021, Positive, Last updated: 01/02/2021 -
List item
Summary of opinion: Koselugo (new)
selumetinib, opinion date: 22/04/2021, Positive, Last updated: 23/04/2021